Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report

BACKGROUND: Tamoxifen, a common anti-estrogen breast cancer medication, is a prodrug that undergoes bioactivation via cytochrome P450 enzymes, CYP2D6 and to a lesser degree, CYP3A4 to form the active metabolite endoxifen. With an increasing use of oral anti-cancer drugs, the risk for drug-drug inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Sara L., Teft, Wendy A., Kim, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864908/
https://www.ncbi.nlm.nih.gov/pubmed/27169677
http://dx.doi.org/10.1186/s12885-016-2342-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864908/
https://www.ncbi.nlm.nih.gov/pubmed/27169677
http://dx.doi.org/10.1186/s12885-016-2342-x

Ejemplares similares